Clinical Research Directory
Browse clinical research sites, groups, and studies.
Aleniglipron Hepatic Impairment Study
Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Summary
The purpose of this study is to evaluate the PK of aleniglipron in participants with Hepatic Impairment to establish scientifically guided dosing recommendations in these special patient populations.
Official title: A Phase 1, Single-Dose, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Aleniglipron Pharmacokinetics
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2026-10
Completion Date
2027-12
Last Updated
2026-10-13
Healthy Volunteers
No
Conditions
Interventions
Aleniglipron
administered orally
Locations (2)
Research Site
Orlando, Florida, United States
Research Site
San Antonio, Texas, United States